Le Lézard
Classified in: Health, Business
Subject: FNC

Primus Capital Funds Makes Major Investment in Transparency Leader Healthcare Bluebook


NASHVILLE, Tenn., Oct. 4, 2017 /PRNewswire/ -- Healthcare Bluebook, Inc. ("Healthcare Bluebook") announced that it has received a major growth investment from Primus Capital Funds ("Primus").  Healthcare Bluebook is the leading independent provider of healthcare price and quality transparency solutions.  Healthcare Bluebook's current management team will continue to lead the company; and the investment by Primus will accelerate Healthcare Bluebook's rapid rise as the preferred transparency solution used by employers, consumers and third-party administrators.

Healthcare Bluebook helps people save money on healthcare by showing them pricing and quality differences for common procedures at facilities in their area?charges that can vary by 2X to 10X.  We empower people with simple, clear price and quality information so they can find the best value.

Healthcare Bluebook's purpose is to protect patients by exposing the truth and empowering choice.  In every US metro area, local prices for the same healthcare service can vary by 2X-10X depending on where a patient receives care ? with no difference in quality or outcomes.  Lack of price and quality transparency causes consumers, who are facing ever increasing deductibles and out of pocket costs, to overpay for care. Similarly, employers who sponsor health benefits also waste billions of dollars on overpriced, low-quality care.

Healthcare Bluebook's simple, intuitive transparency solution allows consumers to find the highest quality care at the best price.  Bluebook is trusted by over 3,000 employers and supports many leading third-party administrators.

Phil Molner, Managing Partner of Primus, commented, "We were attracted to Healthcare Bluebook by the significant value its solutions offer employers and employees by enabling patients to make informed decisions as healthcare consumers.  This is of tremendous importance given the continued growth in patient financial responsibility against a backdrop of the increasing prevalence of high deductible health plans and unsustainable long-term medical cost trends."  Chris Welch, Principal of Primus, added, "Healthcare Bluebook has had tremendous success to date by offering forward-thinking solutions to the market.  We are excited to partner with the team to build upon the company's legacy of innovation."

The Primus investment will allow Healthcare Bluebook to continue to advance their market-leading solutions to solve the most vexing problems in healthcare, ensuring that more patients can receive quality care at an affordable price.  The additional resources will also help accelerate Healthcare Bluebook's growth, enabling its solutions to reach more employers.

Jeffrey Rice, MD, Chief Executive Officer of Healthcare Bluebook commented, "The investment from Primus and the expertise they bring to Bluebook will help us remain at the vanguard of healthcare transparency and patient engagement.  We are very fortunate to be partnering with Primus given their industry knowledge and resources as well as their phenomenal track record of helping companies grow rapidly.  Healthcare Bluebook is looking forward to helping more consumers and employers find value in their healthcare experience."

Raymond James served as the exclusive financial advisor to Healthcare Bluebook in the transaction.

About Healthcare Bluebook

Healthcare Bluebook helps people save money on healthcare by showing them pricing and quality differences for common procedures at facilities in their area?charges that can vary by 2X to 10X.  We empower people with simple, clear price and quality information so they can find the best value.  Healthcare Bluebook works with employers to make healthcare price and quality transparency available to their employees and directly via our website and mobile apps to provide Fair Pricetm information to everyone.  www.healthcarebluebook.com 

About Primus

Primus is a growth-oriented private equity firm that invests in leading healthcare, software, and technology-enabled services companies. Primus partners with exceptional management teams to accelerate growth, improve operating performance, and increase value of the companies in which they invest. Primus pursues buyouts, control and minority recapitalizations, secondary share purchases and expansion financings; this flexible approach enables Primus to engage with business owners and design tailored investment structures to meet the particular needs of the transaction. For more about Primus, please visit www.primuscapital.com.

Primus is a growth-oriented private equity firm that invests in leading healthcare, software, and technology-enabled services companies

SOURCE Healthcare Bluebook


These press releases may also interest you

at 08:00
Interviews available with RTOERO experts, Canadian and international speakers. WHEN:         Wednesday, May 15          (7?9PM)Thursday, May 16              (8:30AM?8PM) Friday, May 17                   (8:30AM?12:15PM) WHERE:      ...

at 08:00
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its recently...

at 07:45
IntelGenx Technologies Corp. (the "Company" or "IntelGenx") announces that, at the annual meeting of shareholders of the Company held on May 7, 2024 (the "Annual Meeting"), shareholders voted in favour of all items of business put forth by the...

at 07:30
Carisma Therapeutics Inc.  ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using...

at 07:30
NeuroTherapia, an early-stage clinical pharmaceutical company, announced today that it has received a grant from the Alzheimer's Association Part the Cloud program for the development of its first-in-class drug, NTRX-07, for the treatment of...

at 07:30
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today that it has...



News published on and distributed by: